Overall, DHA targets the miR-200b–BMI-1/VEGF-A axis to suppress cancer stemness and metastatic potential, highlighting its therapeutic promise in overcoming the limitations of standard chemotherapy for ovarian cancer. The gene discussed is BMI1; the disease is ovarian carcinoma.